Oxinium Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.30 M
- Company Age 10 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 42.67%
- Profit Growth -2.55%
- Ebitda 1357.66%
- Net Worth 22.27%
- Total Assets 3.27%
About Oxinium Pharmaceuticals
Oxinium Pharmaceuticals Private Limited (OPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 July 2014 and has a history of Ten years and six months. Its registered office is in Kolhapur, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Anjali Patil and Satishkumar Patil serve as directors at the Company.
Company Details
-
Location
Kolhapur, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999PN2014PTC151815
-
Company No.
151815
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Jul 2014
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Oxinium Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anjali Patil
|
Director | 14-Jul-2014 | Current |
|
Satishkumar Patil
|
Director | 14-Jul-2014 | Current |
Financial Performance of Oxinium Pharmaceuticals.
Oxinium Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 42.67% increase. The company also saw a slight decrease in profitability, with a 2.55% decrease in profit. The company's net worth Soared by an impressive increase of 22.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oxinium Pharmaceuticals?
In 2018, Oxinium Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Pios Medilinks Private LimitedAnjali Patil and Satishkumar Patil are mutual person
-
Nekszen Academy Foundation
Anjali Patil and Satishkumar Patil are mutual person
-
Dnyanodaya Balvikas Foundation
Satishkumar Patil is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Oxinium Pharmaceuticals?
Unlock and access historical data on people associated with Oxinium Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oxinium Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oxinium Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
